U.S.-based clinical-stage medical electroceutical company Pulse Biosciences Inc. revealed that it has closed its rights offering at $45 million.
Pulse Biosciences sold 3.6 million common stock units at a price of $12.6 per unit. After giving effect to the offering, the company has 20.6 million shares of common stock issued and outstanding.
Prior to the rights offering, the board of directors purchased an aggregate of 3.1 million units for an additional investment of approximately $39.5 million and is now owning 44 percent of the common stock.
U.S.-based stock transfer and registrar services provider Broadridge Corporate Issuer Solutions, Inc. acted as subscription agent for the offering.